Albany, NY -- (SBWIRE) -- 11/07/2018 -- ResearchMoz.us has announced the addition of a report, titled "Global Market Study on Progressive Multifocal Leukoencephalopathy Treatment". The report on the global progressive multifocal leukoencephalopathy market offers a granular assessment of the current outlook of the market, emerging avenues, prominent opportunities, competitive landscape, and major technological advances.
The global progressive multifocal leukoencephalopathy treatment market is forecast to garner a CAGR of 2.8% from 2018 to 2026.
The growing health burden of HIV/AIDS in numerous middle- and low-income countries, coupled with increasing prevalence of HIV infections, in various parts of the world is a key factor driving the demand the progressive multifocal leukoencephalopathy treatments market. The increasing prevalence of progressive multifocal leukoencephalopathy (PML) is a key factor boosting the market. The rising worldwide population with hematological malignancy is also bolstering the demand for progressive multifocal leukoencephalopathy treatments.
Get a Sample PDF: https://www.researchmoz.us/enquiry.php?type=S&repid=1907257
The progressive multifocal leukoencephalopathy treatments market is expected to witness rapid impetus from the growing trend of reimbursement for HIV and cancer treatments in several countries. The progress in treatment options such as the rising use of anti-retroviral and antivirals is catalyzing the expansion of the market. Rapid advances being made in the testing and diagnostics, coupled with advancements in healthcare infrastructures, are catalyzing the growth of the market. These advances are being increasingly fueled by government initiatives in various countries.
Of all the regional markets for progressive multifocal leukoencephalopathy treatments, North America is expected to be the leading market throughout the assessment period. The substantial demand is attributed to owing to the increasing prevalence of HIV infection. The growing awareness about the therapeutics and diagnostics for hematological malignancies along with progressive multifocal leukoencephalopathy is a notable factor accentuating the market. The North America is trailed by Europe.
Meanwhile, Asia Pacific is expected to witness substantial steady growth over the assessment period. The prevalence of HIV infection in the regional population, especially in India and China, is a crucial factor bolstering the demand for the treatments. The global progressive multifocal leukoencephalopathy treatments market is expected to witness rapid strides by the growing emphasis on research and development in various developing and developed economies for understanding the etiology and pathophysiology of rare diseases
Efforts are being made by companies to develop novel treatments that can control the infection by John Cunningham virus. This is expected to unlock promising prospects in the market. Top players are spending substantial sums on R&D to improve the efficacy of their therapies and effectiveness of the treatments for progressive multifocal leukoencephalopathy.
Some of the leading players operating in the progressive multifocal leukoencephalopathy treatment market are Bristol-Myers Squibb Company, AbbVie Inc., F. Hoffmann-La Roche AG, Novartis AG, Allergan Plc. (Actavis Plc.), Gilead Sciences, Sanofi S.A., GlaxoSmithKline Plc, and Pfizer, Inc.